Thomson Jodi M, Distler Anne M, Prati Fabio, Bonomo Robert A
Department of Pharmacology, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USA.
J Biol Chem. 2006 Sep 8;281(36):26734-44. doi: 10.1074/jbc.M603222200. Epub 2006 Jun 27.
Inhibitor-resistant class A beta-lactamases are an emerging threat to the use of beta-lactam/beta-lactamase inhibitor combinations (e.g. amoxicillin/clavulanate) in the treatment of serious bacterial infections. In the TEM family of Class A beta-lactamases, single amino acid substitutions at Arg-244 confer resistance to clavulanate inactivation. To understand the amino acid sequence requirements in class A beta-lactamases that confer resistance to clavulanate, we performed site-saturation mutagenesis of Arg-244 in SHV-1, a related class A beta-lactamase found in Klebsiella pneumoniae. Twelve SHV enzymes with amino acid substitutions at Arg-244 resulted in significant increases in minimal inhibitory concentrations to ampicillin/clavulanate when expressed in Escherichia coli. Kinetic analyses of SHV-1, R244S, R244Q, R244L, and R244E beta-lactamases revealed that the main determinant of clavulanate resistance was reduced inhibitor affinity. In contrast to studies in the highly similar TEM enzyme, we observed increases in clavulanate k(inact) for all mutants. Electrospray ionization mass spectrometry of clavulanate inhibited SHV-1 and R244S showed nearly identical mass adducts, arguing against a difference in the inactivation mechanism. Testing a wide range of substrates with C3-4 carboxylates in different stereochemical orientations, we observed impaired affinity for all substrates among inhibitor resistant variants. Lastly, we synthesized two boronic acid transition state analogs that mimic cephalothin and found substitutions at Arg-244 markedly affect both the affinity and kinetics of binding to the chiral, deacylation transition state inhibitor. These data define a role for Arg-244 in substrate and inhibitor binding in the SHV beta-lactamase.
耐抑制剂的A类β-内酰胺酶对β-内酰胺/β-内酰胺酶抑制剂联合制剂(如阿莫西林/克拉维酸)用于治疗严重细菌感染构成了新的威胁。在A类β-内酰胺酶的TEM家族中,位于第244位的精氨酸发生单氨基酸取代可导致对克拉维酸失活产生抗性。为了解A类β-内酰胺酶中赋予对克拉维酸抗性的氨基酸序列要求,我们对肺炎克雷伯菌中发现的相关A类β-内酰胺酶SHV-1的第244位精氨酸进行了位点饱和诱变。在第244位精氨酸发生氨基酸取代的12种SHV酶在大肠杆菌中表达时,对氨苄西林/克拉维酸的最低抑菌浓度显著增加。对SHV-1、R244S、R244Q、R244L和R244Eβ-内酰胺酶的动力学分析表明,克拉维酸抗性的主要决定因素是抑制剂亲和力降低。与对高度相似的TEM酶的研究不同,我们观察到所有突变体的克拉维酸k(inact)均增加。对克拉维酸抑制的SHV-1和R244S进行电喷雾电离质谱分析,结果显示几乎相同的质量加合物,这表明失活机制没有差异。用不同立体化学取向的具有C3-4羧酸盐的多种底物进行测试,我们观察到耐抑制剂变体对所有底物的亲和力均受损。最后,我们合成了两种模拟头孢噻吩的硼酸过渡态类似物,发现第244位精氨酸的取代显著影响与手性脱酰基过渡态抑制剂结合的亲和力和动力学。这些数据确定了第244位精氨酸在SHVβ-内酰胺酶的底物和抑制剂结合中的作用。